Thursday, 12 April 2012 14:05

Sharon Begley´s "Wired" Part I

On this spring afternoon, the 44-year-old CEO of San Diego- based biotech company Cytori Therapeutics pulls out his laptop, launches a PowerPoint presentation, and there they are: conical and cantaloupy. As through Ds, beige and pink and taupe and tan, more breasts than you might see in a women's locker room, never mind in the middle of a lunch table.

A passing waiter does a double take at this lively slide show, but Calhoun is oblivi­ous. He's talking excitedly about how these women's bodies led him and his team of sci­entists to a discovery in tissue engineer­ing, a process that could well be one of the most momentous medical advances of the 21st century: the use of stemcells..... specifically stem-cell enriched adipose (fat) tissue—to enhance, heal, and rebuild injured or damaged organs.

Published in Media "Classics"
Wednesday, 01 February 2012 10:50

Cytori- The Basic science of ADRCs

The basic science of Cytori- Properties of ADRC´s versus other cell sources

This comes straight from the Cytori homepage:

Science & Technology

Cytori Therapeutics’ goal is to provide access to clinical grade Adipose-Derived Stem and Regenerative Cells (ADRCs). ADRCs, sometimes referred to as stromal vascular fraction cells, are a heterogeneous or mixed population of cells found in adipose tissue. This population includes adult stem cells, endothelial progenitor cells, leukocytes, endothelial cells, and vascular smooth muscle cells. Autologous adult stem and regenerative cells are thought to promote healing of scarred or injured tissue.

While we are learning more about the exact mechanisms every day, it is believed that this heterogeneous population of cells influences the local environment via cell-to-cell signaling, immune modulation, and differentiation into other cell types.

Published in Cytori- Its Technology
Friday, 03 February 2012 15:48

Mechanisms of Therapeutic Action of ADRCs

In the Wall Street press one always reads, when the theme "stem cells" comes up, what the difference in adult- and embryonic cell differentiation potential is and what these magic things all can do, or what they cant do. Words like pluripotency, multipotency and sometimes even the word progenitor cell come up and are the buzz words, in providing an explanation of whats good or bad- which stock you should buy or which one should not touch.

This is very misleading and a lot of rubbish,...

Published in Cytori- Its Technology

There seem to be several misconceptions or maybe just different opinions about the ability for Cytori to protect the IP, which went into the designing- and engineering of the Celution range of products. Thereto different opinions about the technical superiority of the same system. I do not think the following write-up will eliminate differences of opinion, but provides sufficient additional information to provide a clearer picture.

Presently we have the Celution 700 system designed specially for the US- this in respect of the clarity to convey the individual "approved" predicate devices- is awaiting FDA approval still.

The FDA 510K application was filed several times- the approval denied as many times, but those decisions were appealed and are going in front of a court in April 2012, which is NOT FDA prejudiced.

Published in Cytori- Its Technology
Thursday, 02 February 2012 11:50

Cytori´s Intellectual Property Position

Build-up of Cytori´s Intellectual Property rights

Especially with an emerging- and most likely disruptive technology, the protection of one´s IP is of prime importance.

Obviously there are several ways to protect the business- secrecy- and privacy- for instance are also part of that, which is one of the reasons why I am doing this Investor HP- there is more to it than the eye sees at Cytori, meaning disclosure of a public company like Cytori is a constant balancing act between shareholder´s interest and the development of the Company itself, in my opinion. Thats why I believe the position of internal legal council is also a very important one.

Published in Cytori- Its Technology
Page 1 of 2

Copyright Information

Copyright Fas Kuiters © 2016 All Rights Reserved.
This page is made with Joomla CMS and its various templates designed by Fas Kuiters with the excellent Themler tool.



Shared Spreadsheet Links

DOV´s Revised Projections for the Periods 2017 until 2020

Shareble link : HERE

Fas Kuiters Websites